Gastrointestinal Tract - Original Article

Irritable Bowel Syndrome on Inflammatory Bowel Disease in Deep Remission: No Relation with Remission Deepening and Inflammation

Volume 32 · Issue 10 Publish Date: October 15, 2021
Orhan Sezgin Burcu Boztepe Enver Üçbilek Engin Altintas Havva Didem Celikcan
Full Text PDF
DOI
Similar Articles

Published In

Turkish Journal of Gastroenterology

Volume 32 · Issue 10

Pages: 870-878

History

Published Online: October 15, 2021

Copyright © 2021 Orhan Sezgin, Burcu Boztepe, Enver Üçbilek, Engin Altintas, Havva Didem Celikcan

Orhan Sezgin
Department of Gastroenterology, Mersin University Faculty of Medicine, Mersin, Turkey
Burcu Boztepe
Haydarpaşa Numune Education and Research Hospital, Internal Medicine, İstanbul, Turkey
Enver Üçbilek
Department of Gastroenterology, Mersin University, School of Medicine, Mersin
Engin Altintas
Mersin University, Faculty of Medicine, Gastroenterology Department, Mersin, Turkey
Havva Didem Celikcan
Department of Biostatistics, Faculty of Medicine, Mersin University, Mersin, Turkey
Sezgin, O., Boztepe, B., Üçbilek, E., Altintas, E., & Celikcan, H. D. (2021). Irritable Bowel Syndrome on Inflammatory Bowel Disease in Deep Remission: No Relation with Remission Deepening and Inflammation. Turkish Journal of Gastroenterology, 32(10), 870–878. https://doi.org/10.5152/tjg.2021.20806
Endnote/Zotero/Mendeley (RIS) BibTeX
Full Text Full Text PDF

Abstract

Background: The aim of the study was to establish the frequency of irritable bowel syndrome (IBS) in patients with inflammatory bowel disease (IBD) in clinical, endoscopic, and histologic remission and in relation to both the depth of remission and inflammation markers. Methods: Patients with ulcerative colitis (UC) and with Crohn’s disease (CD) in clinical remission for at least 6 months were enrolled in the study. All of the patients underwent colonoscopy, and biopsy specimens were taken to evaluate endoscopic and histopathologic remission. Patients were evaluated according to Rome III criteria for IBS. Fecal calprotectin level and blood samples for C-reactive protein (CRP), sedimentation rate, and fibrinogen levels were studied. Results: IBS frequency was 20.9% in UC cases and 28.9% in CD cases in clinical remission. Rates with and without endoscopic remission in UC (20.5% vs. 22.2%, P = .727) and CD (25% vs. 33.3%, P = .837, respectively) were not different. Similarly, rates with and without histopathologic remission in UC (15.7% vs. 26.6%, P = .723), and CD (21.4% vs. 33.3%, P = .999) were not statistically different. Also, it was not related to inflammation markers. Conclusion: IBS frequency among IBD patients with remission was in a substantial rate; these rates kept up with the process of deep remission and even complete mucosal healing and were irrelevant to inflammation.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >> 
Article Info
Published In
Journal Turkish Journal of Gastroenterology
Volume / Issue Volume 32 · Issue 10
Pages 870-878
DOI 10.5152/tjg.2021.20806
History
Published Online October 15, 2021
Copyright
Copyright (c) 2021 Orhan Sezgin, Burcu Boztepe, Enver Üçbilek, Engin Altintas, Havva Didem Celikcan
Affiliations
Orhan Sezgin
Department of Gastroenterology, Mersin University Faculty of Medicine, Mersin, Turkey
Burcu Boztepe
Haydarpaşa Numune Education and Research Hospital, Internal Medicine, İstanbul, Turkey
Enver Üçbilek
Department of Gastroenterology, Mersin University, School of Medicine, Mersin
Engin Altintas
Mersin University, Faculty of Medicine, Gastroenterology Department, Mersin, Turkey
Havva Didem Celikcan
Department of Biostatistics, Faculty of Medicine, Mersin University, Mersin, Turkey
Cite this Article
Sezgin, O., Boztepe, B., Üçbilek, E., Altintas, E., & Celikcan, H. D. (2021). Irritable Bowel Syndrome on Inflammatory Bowel Disease in Deep Remission: No Relation with Remission Deepening and Inflammation. Turkish Journal of Gastroenterology, 32(10), 870–878. https://doi.org/10.5152/tjg.2021.20806
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX
Outlines